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Abstract
A fatal case of disseminated Scopulariopsis brevicaulis infection in an allogeneic stem cell transplant recipient is described. The patient was
initially thought to have pulmonary aspergillosis, on the basis of clinical signs and antigenaemia, but Aspergillus was not isolated by culture.
Scopulariopsis brevicaulis was subsequently isolated from skin and then from sputum and stool. Further investigation revealed that the infec-
tion had spread from a primary pulmonary site to the skin. A review of the literature underscores the difficulty of diagnosing infections
caused by such emerging fungal pathogens and the poor outcome of immunocompromised patients with non-Aspergillus mould infections.
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Introduction
The ascomycete Scopulariopsis brevicaulis (teleomorph Micro-
ascus brevicaulis) is a soil saprophyte widely distributed in
nature. It has been isolated from soil and from a wide
range of plants and organic substrates [1]. In immunocom-
petent patients, S. brevicaulis has mainly been associated
with onychomycosis, accounting for 1–10% of such infec-
tions [2,3]. It can occasionally cause cutaneous lesions [4,5]
and more severe infections following traumatic or surgical
injury [6,7]. During the last two decades, an increasing
number of severe cases of S. brevicaulis infection have been
reported in immunocompromised hosts, ranging from local-
ized infections to invasive hyalohyphomycosis. Deep infec-
tions carry a poor prognosis, owing to diagnostic difficulties
and the lack of a consensus therapeutic strategy. A combi-
nation of surgery and antifungal drug therapy seems to be
the treatment of choice, but S. brevicaulis has been
reported to be resistant to amphotericin B, terbinafine
and azoles in vitro, and the indications for surgery are
limited [8].
Here we describe a case of disseminated S. brevicaulis
infection in an allogeneic stem cell graft recipient. Treatment
with single-agent amphotericin B and with an antifungal drug
combination (amphotericin B plus voriconazole) was ineffec-
tive. We also examine other reports of severe Scopulariopsis
infections in immunocompromised patients, focusing on diag-
nosis and treatment.
Case report
In December 2006 a 38-year-old woman was admitted to
Nancy hospital for acute myelogenous leukaemia. Seven
months later, in June 2007, she underwent myeloablative
conditioning and allogeneic peripheral blood stem cell trans-
plantation from a mismatched unrelated donor. One month
post-transplant, and despite graft-versus-host disease (GVHD)
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prophylaxis with cyclosporin and mycophenolate, she devel-
oped acute GVHD and extensive chronic GVHD (gut, liver
and skin) in October 2007. She was treated with steroids, a
TNF-a antagonist and alemtuzumab. Posaconazole was used
for antifungal prophylaxis.
In November 2007 she developed signs of Epstein–Barr
virus-induced post-transplant lymphoproliferative disorder with
pulmonary involvement. Computed tomography (CT)
showed a lesion in the upper right lung evoking pulmonary
aspergillosis (Fig. 1). Posaconazole was empirically switched
to liposomal amphotericin B (3 mg/kg/day). After 2 weeks
the lesion had shrunk, but she developed a pneumopathy a
few days later. Presuming a bacterial infection, treatment
with teicoplanine and ceftazidime was started and her condi-
tion improved. Since the patient’s serum was positive for
Aspergillus galactomannan (index 0.57–2.03, twice weekly)
(Platelia Aspergillus, Bio-Rad), liposomal amphotericin B (3
mg/kg/day) was combined with caspofungin (70 mg loading
dose followed by 50 mg daily). On 7 January (day 190 post
transplant) she developed necrotic cutaneous lesions on her
legs and face, c. 2 mm in diameter with an inflammatory
perimeter. Biopsy showed numerous septate hyphae by
direct observation after Noir Chlorazol staining (Fig. 2a).
Microscopic examination of histological sections stained with
lactophenol blue, periodic acid–Schiff, haematoxylin–eosin
(not shown) and Gomori-methamine silver revealed branch-
ing, septate hyphae and many vesicular swellings of different
sizes (Fig. 2b–d) The dermis, hypodermis and subcutaneous
vessels were invaded by numerous hyphae (Fig. 2b,c).
Opportunistic cutaneous fusariosis was suspected, as Fusa-
rium is one of the most significant emerging fungal pathogens
in the high-risk population to which this patient belonged.
The dose of amphotericin B (3 mg/kg/day) was increased to
10 mg/kg/day and caspofungin was replaced by voriconazole
(200 mg twice a day), based on recent published data [9].
To obtain the most accurate aetiological diagnosis possible
and to avoid inhibition of fungal growth that would prevent
identification, DNA was extracted from the biopsy specimen
and successfully amplified with panfungal primers ITS1-ITS4
[10]. Molecular identification of S. brevicaulis was achieved by
sequencing. Finally, cultures of the biopsy specimen grew
whitish colonies after only 2 days on Sabouraud agar at
27C. The colonies developed a brown powdery surface,
with a reverse cream-coloured to brownish. Microscopic
examination revealed hyaline annelloconidia, 3–4 lm in diam-
eter, originating from penicillate flask-shaped conidiophores
attached to hyaline septate hyphae. The conidia were mostly
rough-walled with a truncated base and occurred in chains.
The characteristic morphology of these conidia and conidio-
phores was consistent with S. brevicaulis (Fig. 1d). The isolate
was sent to the Pasteur Institute in Paris for confirmation of
the species identification and for susceptibility testing. The
MICs were the following: amphotericin B, itraconazole and
posaconazole ‡8 mg/L, flucytosine ‡64 mg/L, voriconazole
8 mg/L, and caspofungin 0.5 mg/L.
On 17 January, S. brevicaulis was detected in sputum using
PCR and fungal culture. CT performed on 23 January
showed worsening of the pulmonary lesions and the occur-
rence of bilateral renal lesions. During the following days the
fungus was also isolated from stool. These results showed
the dissemination of S. brevicaulis infection. The patient’s con-
dition continued to worsen and she died on 29 January of
multiorgan failure, 212 days after transplantation.
Discussion
We describe a case of widely disseminated S. brevicaulis infec-
tion in a woman with acute GHVD after stem cell transplan-
tation. The patient was highly vulnerable to opportunistic
infections, due to her severe immunosuppression, acute
GVHD, and lengthy exposure to broad-spectrum antibiotics.
Although significant advances have been made in the preven-
tion of bacterial and fungal diseases in bone marrow trans-
plant patients, the incidence of mould infections has
increased in recent years [11]. The most common fungal
pathogen in this setting remains Aspergillus. Less common
fungi include Zygomycetes, non-Aspergillus hyalohyphomyce-
tes (Fusarium sp., Scedosporium sp.) and phaeohyphomycetes
(Exophiala dermatitidis, etc.) [12,13]. Human Scopulariopsis
infections are relatively rare but are increasingly reported,
particularly in immunocompromised hosts, with localized
forms such as recurrent subcutaneous infections [14,15], pul-
monary fungus ball [16], skin lesions [17,18], keratitis [19–
21], endophthalmitis [6,22], and also pneumonia [23,24],
FIG. 1. Chest computed tomography scan showing an abnormality
in the right upper lung suggestive of aspergillosis. Scopulariopsis brevi-
caulis was subsequently isolated from skin, sputum and stools.
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endocarditis [25–28], brain abscess [29], meningitis [30], and
fatal disseminated infections [31–37].
As with other invasive hyalohyphomycoses, Scopulariopsis
infections are difficult to diagnose, and this often delays
appropriate therapy. Clinical manifestations cannot be used
to distinguish between infections due to Aspergillus and other
hyalohyphomycetes [37]. Cultures, including blood culture,
are usually negative, and there are no commercial serological
tests. Histopathological examination, the gold standard for
the diagnosis of invasive mycoses, as well as direct mycologi-
cal examination, reveal septate hyphae that are indistinguish-
able from those of other hyalohyphomycetes (Aspergillus,
Fusarium, Scedosporium, etc.). Thus, many non-Aspergillus
mould infections may be misdiagnosed as Aspergillus infection
on the basis of clinical or histopathological features, as in the
case reported by Wagner et al. (2005). Our patient was ini-
tially thought to have pulmonary aspergillosis on the basis of
her clinical features and positive antigenaemia, even though
Aspergillus was not isolated by culture. Subsequent isolation
of S. brevicaulis from lesions of previously healthy skin sug-
gested dissemination of the fungus from the lungs to the
skin. In such cases, molecular tools may be particularly help-
ful for identifying the pathogen and hastening appropriate
treatment [38].
A positive Aspergillus galactomannan test has previously
been described in this setting [36]. The test detects galacto-
mannan, which is widely distributed in filamentous fungi such
as Aspergillus and Penicillium. In our patient the positive result
may have been due to cross-reactivity with S. brevicaulis cell
wall components, as no other fungus was isolated. Moreover,
the patient had not been treated with piperacillin–tazobac-
tam, which has been linked to false-positive galactomannan
ELISA results [39]. The positive result is also consistent with
haematogenous spread of S. brevicaulis from the lungs to the
skin.
A similar case of secondary cutaneous infection by Micro-
ascus (a teleomorph of Scopulariopsis) from a primary pulmo-
nary site has been described in a 12-year-old boy with acute
myelogenous leukaemia who received autologous bone
marrow transplantation [35]. The infection resolved after
therapy with a colloidal dispersion formulation of amphoteri-
cin B (Amphocil). As in most other reports, lipid-amphoteri-
cin B therapy failed in our patient, as did voriconazole and
also caspofungin lipid-amphotericin B combination therapy.
Therapeutic approaches mentioned in the literature include
debridement or excision of necrotic tissue plus pro-
longed single-agent or combination antifungal therapy
[2,8,27,37,40,41].
In our case, the patient was receiving posaconazole for
antifungal prophylaxis. The inefficacy of posaconazole in pre-
venting rare pathogens that are less responsive to the most
frequently used prophylactic drugs is noteworthy. Scopulari-
opsis infections are uncommon but may be encountered as
breakthrough infections like other moulds in patients under
antifungal prophylaxis. For example, cases have been pub-
lished that occurred in patients under amphotericin B lipid
complex [36,37]. Several breakthrough infections due to
fungi other than Scopulariopsis have also been described in
(a) (c)
(b) (d) FIG. 2. (a) Direct examination after Noir
Chlorazol staining revealing thin septate
hyphae. (b) Hyphae, annellides and caten-
ulate annelloconidia of the Scopulariopsis
brevicaulis anamorph (lactophenol blue).
(c) Periodic acid-Schiff and (d) Gomori
methenamine silver (Grocott) stains of
the skin biopsy sample, showing septate
hyphae and branching at an angle of 45.
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patients under posaconazole prophylaxis (Rhizopus, Scedos-
porium prolificans, etc.) [42,43]. A recent paper has also
reported the case of a woman with acute myeloid leukaemia
who received 4 months of posaconazole for the labelled indi-
cation of prophylaxis of Candida and Aspergillus infections.
The patient developed a fatal invasive sinus infection diag-
nosed as a mixed Aspergillus and Mucor aetiology. Upon
investigation it was found that the patient did not self-admin-
ister posaconazole as required in the product labelling. This
may have led to drug failure in this patient. The disadvantage
to oral administration of posaconazole is that it is not under
medical control and may increase the risk of such break-
through mycoses [44].
The strain isolated from our patient showed in vitro resis-
tance to amphotericin B, itraconazole, posaconazole, flucyto-
sine and voriconazole. In a study of S. brevicaulis, all isolates
were highly resistant to amphotericin B, itraconazole, posaco-
nazole, voriconazole, terbinafine as well as caspofungin [45].
In some large in vitro studies, voriconazole was more effective
than amphotericin B and itraconazole against S. brevicaulis
[46,47]. Some combinations have shown synergy for S. brevi-
caulis isolates in vitro, including terbinafine plus fluconazole
and itraconazole plus voriconazole [48]. Amphotericin B plus
caspofungin, posaconazole plus caspofungin, and voriconazole
plus caspofungin also showed synergy against some isolates
[45]. Posaconazole plus terbinafine was synergistic for 68% of
the isolates (2006). In contrast, few data are available on the
clinical efficacy of combination therapy. In a case of a recur-
rent S. brevicaulis subcutaneous infection occurring 6 years
after liver transplantation, a combination of surgery and long-
term oral terbinafine resulted in a favourable outcome [14].
In another case of invasive sinonasal infection by S. candida,
the patient survived after treatment with colony-stimulating
factor, amphotericin B and itraconazole, without undergoing
radical surgical debridement [23]. Isidro et al. [25] recom-
mended initial empiric use of intravenous amphotericin B,
alone or in combination with voriconazole or itraconazole,
when Scopulariopsis is identified in a clinical specimen. Out-
come depends mainly on immune status, the time from onset
to diagnosis, and the extension of the infection.
As in previous reports, this case emphasizes the need for
early accurate aetiological diagnosis and for more effective
therapeutic strategies for such potentially life-threatening
fungal infections.
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